Titre : Hémoglobinurie

Hémoglobinurie : Questions médicales fréquentes

Termes MeSH sélectionnés :

Plasma Exchange
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hémoglobinurie : Questions médicales les plus fréquentes", "headline": "Hémoglobinurie : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hémoglobinurie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-28", "dateModified": "2025-02-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hémoglobinurie" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéinurie", "url": "https://questionsmedicales.fr/mesh/D011507", "about": { "@type": "MedicalCondition", "name": "Protéinurie", "code": { "@type": "MedicalCode", "code": "D011507", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.942.750" } } }, "about": { "@type": "MedicalCondition", "name": "Hémoglobinurie", "alternateName": "Hemoglobinuria", "code": { "@type": "MedicalCode", "code": "D006456", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hubert Schrezenmeier", "url": "https://questionsmedicales.fr/author/Hubert%20Schrezenmeier", "affiliation": { "@type": "Organization", "name": "Institute of Transfusion Medicine, University of Ulm, Ulm, Germany." } }, { "@type": "Person", "name": "Austin G Kulasekararaj", "url": "https://questionsmedicales.fr/author/Austin%20G%20Kulasekararaj", "affiliation": { "@type": "Organization", "name": "From the Hematology and Transplant Unit, French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis Hospital (R.P.L., F.S.F.), and Université de Paris (R.P.L.), Paris, Centre Hospitalier Universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse (S.T.), and CHU Lille, Université de Lille, Lille (L.T.) - all in France; the Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen (A.R., F.A.), the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, and the Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen (J.P.), the University of Ulm, the Institute of Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm (H.S., B. Höchsmann), the Department of Oncology, Hematology, and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (P. Schafhausen), and Elblandklinikum Riesa, Riesa (J.S.) - all in Germany; King's College Hospital NHS Foundation Trust (A.G.K., S.G., R.T.), the National Institute for Health and Care Research and Wellcome King's Clinical Research Facility (A.G.K.), King's College London (A.G.K.), and Novartis Pharmaceuticals (C.T.), London, and St. James's University Hospital, Leeds (M.G., R.J.K.) - all in the United Kingdom; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing (B. Han, C.Y.), the Department of Hematology, Tianjin Medical University General Hospital (R.F., H.L.), and the Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (L.Z.), Tianjin, and China Novartis Institutes for BioMedical Research, Shanghai (Z.W., S.L.) - all in China; the Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo (P. Scheinberg), and ABC Medical School, Santo André (V.A.Q.M.) - both in Brazil; the Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland (J.P.M.); Osaka University Graduate School of Medicine, Suita (Y.U.), Kyoto University Hospital, Kyoto (T.K.), and Japanese Red Cross Society Suwa Hospital, Suwa (M.U.) - all in Japan; Duke University School of Medicine and Duke Cancer Institute, Durham, NC (C.M.C.); Unità Operativa Complessa Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (E.D.B.), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (W.B.), Division of Hematology, University of Turin, Città della Salute e della Scienza, Turin (E.B.), Instituto per lo Studio, la Prevenzione e la Rete Oncologica, and Azienda Ospedaliero-Universitaria Careggi, Florence (R.N.), AORN Moscati, Avellino (L.M., A.M.R.), and University of Naples Federico II, Naples (A.M.R.) - all in Italy; Radboud University Medical Center, Nijmegen, the Netherlands (S.M.C.L.); the Hematology Unit, Department of Medicine, Hospital Umum Sarawak, Kuching (L.P.C.), and the Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu (L.W.L.L.) - both in Malaysia; Hospital Clinic of Barcelona (A.G.) and the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (R.P.L., A.G.K., M.G., W.B., S.T., L.T., F.S.F., L.M., A.M.R.) - both in Barcelona; the Department of Hematology and Oncology and the Department of Clinical Pathology, Hualien Tzu Chi Hospital, the Buddhist Tzu Chi Medical Foundation, and the Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan (W.-H.H.); the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (J.H.J.); Medical College of Georgia, Augusta (A.K.); City of Hope Medical Center, Duarte, CA (V.P.); the Department of Laboratory Medicine, National University Hospital, Singapore (E.-S.Y.); Novartis Pharma (C.K., R.L., M.D.) and Novartis BioMedical Research (A.V.) - both in Basel, Switzerland; and Novartis Healthcare Private, Hyderabad, India (P.B., R.K., S.M.)." } }, { "@type": "Person", "name": "Robert A Brodsky", "url": "https://questionsmedicales.fr/author/Robert%20A%20Brodsky", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD." } }, { "@type": "Person", "name": "Jun-Ichi Nishimura", "url": "https://questionsmedicales.fr/author/Jun-Ichi%20Nishimura", "affiliation": { "@type": "Organization", "name": "Osaka University Graduate School of Medicine, Department of Hematology and Oncology." } }, { "@type": "Person", "name": "Britta Höchsmann", "url": "https://questionsmedicales.fr/author/Britta%20H%C3%B6chsmann", "affiliation": { "@type": "Organization", "name": "Institute of Transfusion Medicine, University of Ulm, Ulm, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.", "datePublished": "2022-05-12", "url": "https://questionsmedicales.fr/article/35551087", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2021-050112" } }, { "@type": "ScholarlyArticle", "name": "Thawed plasma (TP) as a substitute for intravenous immune globulin (IVIG) to prevent hypogammaglobulinemia post-therapeutic plasma exchange.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37147249", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.transci.2023.103716" } }, { "@type": "ScholarlyArticle", "name": "Membrane-based therapeutic plasma exchange: Proposed techniques for preventing filter failure.", "datePublished": "2023-06-08", "url": "https://questionsmedicales.fr/article/37287385", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jca.22065" } }, { "@type": "ScholarlyArticle", "name": "Therapeutic plasma exchange in anti-N-methyl-D-aspartate receptor encephalitis.", "datePublished": "2022-10-12", "url": "https://questionsmedicales.fr/article/36165337", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1744-9987.13934" } }, { "@type": "ScholarlyArticle", "name": "Improved recurrence-free survival in patients with HCC with post-transplant plasma exchange.", "datePublished": "2023-04-10", "url": "https://questionsmedicales.fr/article/37029084", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/LVT.0000000000000147" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Manifestations urologiques", "item": "https://questionsmedicales.fr/mesh/D020924" }, { "@type": "ListItem", "position": 5, "name": "Protéinurie", "item": "https://questionsmedicales.fr/mesh/D011507" }, { "@type": "ListItem", "position": 6, "name": "Hémoglobinurie", "item": "https://questionsmedicales.fr/mesh/D006456" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hémoglobinurie - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hémoglobinurie", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hémoglobinurie", "description": "Comment diagnostiquer l'hémoglobinurie ?\nQuels tests sont utilisés pour confirmer l'hémoglobinurie ?\nQuels signes indiquent une hémoglobinurie ?\nL'hémoglobinurie est-elle visible à l'œil nu ?\nQuels autres tests peuvent être nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hémoglobinurie", "description": "Quels sont les symptômes de l'hémoglobinurie ?\nL'hémoglobinurie cause-t-elle des douleurs ?\nPeut-on avoir de la fièvre avec l'hémoglobinurie ?\nL'hémoglobinurie entraîne-t-elle une anémie ?\nY a-t-il des signes urinaires associés ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hémoglobinurie", "description": "Comment prévenir l'hémoglobinurie ?\nLes infections urinaires peuvent-elles être évitées ?\nY a-t-il des mesures spécifiques pour les athlètes ?\nLes maladies héréditaires peuvent-elles être évitées ?\nL'alimentation joue-t-elle un rôle ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hémoglobinurie", "description": "Comment traiter l'hémoglobinurie ?\nLes transfusions sont-elles nécessaires ?\nDes médicaments peuvent-ils aider ?\nL'hydratation est-elle importante ?\nQuand consulter un médecin pour l'hémoglobinurie ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hémoglobinurie", "description": "Quelles complications peuvent survenir ?\nL'hémoglobinurie peut-elle endommager les reins ?\nY a-t-il un risque d'infection ?\nDes problèmes cardiovasculaires peuvent-ils survenir ?\nL'hémoglobinurie peut-elle être fatale ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hémoglobinurie", "description": "Quels sont les facteurs de risque de l'hémoglobinurie ?\nLes athlètes sont-ils plus à risque ?\nLes maladies génétiques augmentent-elles le risque ?\nCertains médicaments sont-ils des facteurs de risque ?\nL'âge influence-t-il le risque d'hémoglobinurie ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Plasma+Exchange&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hémoglobinurie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test urinaire détecte l'hémoglobine libre, souvent accompagné d'analyses sanguines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer l'hémoglobinurie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire comme l'analyse d'urine et la numération des globules rouges sont utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une hémoglobinurie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une urine de couleur rouge ou brune, associée à des douleurs abdominales, peut indiquer l'hémoglobinurie." } }, { "@type": "Question", "name": "L'hémoglobinurie est-elle visible à l'œil nu ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'urine peut apparaître rougeâtre ou brunâtre, mais des tests sont nécessaires pour confirmation." } }, { "@type": "Question", "name": "Quels autres tests peuvent être nécessaires ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests pour évaluer la fonction rénale et rechercher des infections peuvent être requis." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'hémoglobinurie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent urine colorée, douleurs abdominales et fatigue, selon la cause." } }, { "@type": "Question", "name": "L'hémoglobinurie cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales ou lombaires peuvent accompagner l'hémoglobinurie." } }, { "@type": "Question", "name": "Peut-on avoir de la fièvre avec l'hémoglobinurie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fièvre peut survenir si l'hémoglobinurie est causée par une infection sous-jacente." } }, { "@type": "Question", "name": "L'hémoglobinurie entraîne-t-elle une anémie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la destruction des globules rouges peut provoquer une anémie, entraînant fatigue et faiblesse." } }, { "@type": "Question", "name": "Y a-t-il des signes urinaires associés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des mictions fréquentes ou douloureuses peuvent être présents avec l'hémoglobinurie." } }, { "@type": "Question", "name": "Comment prévenir l'hémoglobinurie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les traumatismes, les infections et maintenez une bonne hydratation pour prévenir l'hémoglobinurie." } }, { "@type": "Question", "name": "Les infections urinaires peuvent-elles être évitées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hygiène et une hydratation adéquate aident à prévenir les infections urinaires." } }, { "@type": "Question", "name": "Y a-t-il des mesures spécifiques pour les athlètes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les athlètes doivent éviter les blessures et bien s'hydrater pour prévenir l'hémoglobinurie." } }, { "@type": "Question", "name": "Les maladies héréditaires peuvent-elles être évitées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, mais un suivi médical régulier peut aider à gérer les risques associés aux maladies héréditaires." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut renforcer le système immunitaire et réduire les risques d'infections." } }, { "@type": "Question", "name": "Comment traiter l'hémoglobinurie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dépend de la cause sous-jacente, incluant transfusions ou médicaments." } }, { "@type": "Question", "name": "Les transfusions sont-elles nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions peuvent être nécessaires si l'hémoglobinurie cause une anémie sévère." } }, { "@type": "Question", "name": "Des médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments pour traiter l'infection ou la maladie sous-jacente peuvent être prescrits." } }, { "@type": "Question", "name": "L'hydratation est-elle importante ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hydratation aide à diluer l'urine et à réduire les symptômes de l'hémoglobinurie." } }, { "@type": "Question", "name": "Quand consulter un médecin pour l'hémoglobinurie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si vous avez une urine colorée ou des symptômes associés persistants." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent l'anémie sévère, des lésions rénales et des infections urinaires." } }, { "@type": "Question", "name": "L'hémoglobinurie peut-elle endommager les reins ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une hémoglobinurie prolongée peut entraîner des lésions rénales et une insuffisance rénale." } }, { "@type": "Question", "name": "Y a-t-il un risque d'infection ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hémoglobinurie peut augmenter le risque d'infections urinaires et rénales." } }, { "@type": "Question", "name": "Des problèmes cardiovasculaires peuvent-ils survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une anémie sévère due à l'hémoglobinurie peut entraîner des problèmes cardiovasculaires." } }, { "@type": "Question", "name": "L'hémoglobinurie peut-elle être fatale ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Dans de rares cas, des complications graves peuvent survenir, rendant la situation potentiellement fatale." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'hémoglobinurie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les traumatismes, infections, maladies héréditaires et certains médicaments augmentent le risque." } }, { "@type": "Question", "name": "Les athlètes sont-ils plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les athlètes peuvent être à risque en raison de traumatismes répétés et de déshydratation." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme la drépanocytose augmentent le risque d'hémoglobinurie." } }, { "@type": "Question", "name": "Certains médicaments sont-ils des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments comme les antibiotiques peuvent provoquer une hémoglobinurie." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'hémoglobinurie ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus à risque en raison de maladies sous-jacentes." } } ] } ] }

Sources (10000 au total)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.

Patients with metastatic melanoma rely on PD-(L)1 immunotherapy, but only one-third of patients experience treatment response and all initial responders eventually develop resistance. Tumour-derived e... In this two-arm study, 60 patients with metastatic melanoma progressing on checkpoint inhibition will be accrued. All patients will undergo radiotherapy on days 1-5 (at least one measurable lesion wil... This trial has been approved by the Mayo Clinic Institutional Review Board. It will assess the safety and feasibility of TPE in improving outcomes for PD-(L)1 inhibitor immunotherapy in melanoma. Data... NCT04581382....

Membrane-based therapeutic plasma exchange: Proposed techniques for preventing filter failure.

Therapeutic plasma exchange (TPE) is commonly performed using membrane-based TPE (mTPE) and is prone to filter failure.... We report on 46 patients, with a total of 321 mTPE treatments using the NxStage machine. This was a retrospective study with an aim to evaluate the effect of heparin, pre-filter saline dilution and th... We found that treatments that received both pre-filter heparin and saline had a statistically significant decrease in filter failure rate as compared to those that received neither (28.6% vs. 5.3%, P ... Rate of filter failure in mTPE can be reduced by implementing several therapeutic interventions including pre-filter heparin and pre-filter saline solution. These interventions were not associated wit...

Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review.

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy (TMA), and therapeutic plasma exchange (TPE) is currently the standard treatment. However, TPE sometimes cannot be implemented... The PubMed, Embase, Web of Science and Cochrane Library databases were searched by two investigators independently to collect case reports and clinical studies on TTP patients treated without TPE. Aft... A total of 5338 potentially relevant original studies were identified, from which 21 studies, including 14 cases, 3 case series and 4 retrospective studies, met eligibility requirements and were inclu... Our study shows that TPE-free treatment may not increase the mortality of TTP patients, which provides a new treatment concept for patients with first episodes of TTP. However, the current evidence is...

Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.

Dacomitinib-induced liver injury is often manifested by mild elevations of transaminases and bilirubin, and severe intrahepatic cholestasis caused by dacomitinib for simultaneous taking orally cytochr... The patient was a 69-year-old woman with non-small cell lung cancer (NSCLC) who was prescribed oral dacomitinib for a month; she was given oral loratadine due to "allergic rhinitis" and metoprolol ext... Intrahepatic cholestasis, drug-induced liver injury, and NSCLC.... After admission, the patient was prescribed adenosylmethionine, acetylcysteine, ursodeoxycholic acid capsule, methylprednisolone and fenofibrate for a month, with progressive elevation of liver bioche... The patient was discharged after her liver parameters improved; the parameters remained normal at several follow-up visits, and she renewed the NSCLC regimens without dacomitinib after being evaluated... Dacomitinib can induce severe intrahepatic cholestasis. It is considered that patients with intermediate metabolic CYP2D6 are susceptible to drug-induced liver injury caused by dacomitinib; plasma exc...

Therapeutic Plasma Exchange in Neurological Conditions: An Observation from the Eastern Part of India.

Therapeutic plasma exchange (TPE) is an extracorporeal process of separation of plasma from the cellular components of blood and its replacement with analogous fluids. This process is effective in tre... To evaluate major indications of therapeutic plasma exchange in neurological disorders. To identify major complications associated and factors associated with premature cessation of the therapeutic pl... A total of 508 TPE procedures were performed on 118 patients. In this study 61 patients were male and 57 patients were female. O-blood group was commonest blood group among the patients. GBS is the co... TPE is a safe and effective treatment option for various immune-mediated neurological disorders and should be considered in managing these disorders....

Plasma exchange as an adjunctive therapy in anti-neutrophil cytoplasm antibody-associated vasculitis.

We summarize evidence for the role of therapeutic plasma exchange (TPE) in the treatment of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). TPE rapidly removes ANCA IgG, complem... We analyze data from PEXIVAS and other trials of TPE in AAV, an up-to-date meta-analysis, and recently published large cohort studies.... There remains a role for the use of TPE in AAV in certain groups of patients, in particular those with severe renal involvement (Cr >500 μmol/L or dialysis-dependent). It should be considered in patie...